Compiled Data and Recent Business Analyst -
First, Full proof of OWC being 100% Legit with fully filed and active clinical trials.
- updated filing of OWC Clinical Trials of .OWC MGC cream
https://clinicaltrials.gov/ct2/show/NCT029767...amp;rank=1
Responsible Party: One World Cannabis Ltd.
ClinicalTrials.gov Identifier: NCT02976779 History of Changes
Other Study ID Numbers: OWC-PSO-01
Who is this ClinicalTrials.GOV site?
ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, currently holding registrations from over 230,000 trials from 195 countries in the world.
OWC Pharmaceutical Research Analysis;
OWC Pharmaceutical Research Corp (OTCMKTS: OWCP), through its wholly owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
In fact, the Israeli government is one of the few countries worldwide to approve clinical studies with cannabis.
The company recently announced that it received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical cream compound for treatment of psoriasis and related skin conditions.
Psoriasis cream is one of the major/critical business drivers for the company. It is in final round of efficacy testing before it hits shelves. Management confirmed that this approval is a significant milestone for the company & immediately after approval of psoriasis treatment formulation; OWCP began receiving requests for its topical psoriasis cream product from patients suffering from the condition.
OWCP further added, that after several years of extensive research, they now expect to launch psoriasis cream to the market during second quarter of 2017 or soon thereafter. Beyond psoriasis, it is also pushing multiple myeloma candidates through early stage trials, with the goal of getting the assets into clinical studies before the end of 2017.
OWCP operates in Marijuana industry that has rapidly & recently turned into a multi-billion dollar massive growth market across US and Canada with many new states legalizing it. According to a recent estimates, cannabis market crossed $6.7 billion from the U.S. alone in 2016, and that sale of cannabis are set to rise to $22.8 billion in the U.S. by 2020.
There are only a handful of publicly traded companies focused on meaningful, advanced stage cannabinoid-based, pharmaceutical development.
The growing popularity of this industry is seen as major inflection point for current licensed producers & researchers. In particular, existing cannabis players with sizable market cap & advanced stage product pipeline are expected to grow their (OWC) business with relatively lesser competitive threats.
OWCP is one of the promising entities for cannabis investors. The company has its own IP’s, which commands significant value.
Furthermore, as it move towards approval and commercialization process, the intrinsic value of the company is expected to increase significantly. With a seasoned management team, OWCP is at a critical inflection point.
Description & manufacturing set-up:
OWC Pharmaceutical, through its wholly owned subsidiary, One world Cannabis Ltd, conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. It is also developing unique delivery systems for effective delivery and dosage of medical cannabis. All its research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
One world Cannabis Ltd was set up in 2014 in Israel as a Wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB:OWCP). One World offers OWCP with international access to the best research facilities and researchers in medicinal cannabis.
The state of Israel has been supportive of cannabis study and scientific research since 1960s’ in renown academic and research hospitals. The Medical Cannabis Unit under the Health Minister Office is operating in Israel since 2003.
Major Divisions of the Company:
R&D Division: All OWCP studies are following approved clinical procedures by IRB protocols conducted in Israeli hospitals facilities. Each new product targets a specific disease or medical conditions, with a particular emphasis on identifying unique formulation and efficient delivery systems to optimize the bioavailability of dosage.
Key Cannabis Based Products (IP owned by OWCP) – Likely to be commercialized:
Topical cream: Treatment for different skin diseases starting with tested psoriasis. Estimated market size ~8 Million Psoriasis patients US & Canada (2.5% of population).
Sublingual Soluble tablet: For conditions like, replacement of smoking & pain treatment. Estimated market size – more than 10 million potential patients in the approved MMJ states.
All OWCP Patents,
1. WO/2016/199148 NOVEL CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM) WO 15.12.2016
A61K 31/352
PCT/IL2016/050608 ONE WORLD CANNABIS LTD SINAI, Alon
2. WO/2016/181394 USE OF CANNABIS TO TREAT FIBROMYALGIA, METHODS AND COMPOSITIONS THEREOF WO 17.11.2016
A61K 31/352
PCT/IL2016/050498 ONE WORLD CANNABIS LTD SINAI, Alon
3. WO/2016/147186 PREPARATIONS OF CANNABIS EMULSIONS AND METHODS THEREOF WO 22.09.2016
A61K 9/107
PCT/IL2016/050289 ONE WORLD CANNABIS LTD SINAI, Alon
4. WO/2016/103254 USE OF CANNABIS TO TREAT PSORIASIS WO 30.06.2016
A61K 31/352
PCT/IL2015/051234 ONE WORLD CANNABIS LTD SINAI, Alon
5. WO/2016/098112 NOVEL CONDOM COMPRISING CANNABIS DERIVED COMPOSITIONS FOR ENHANCEMENT OF SEXUAL PLEASURE AND DECREASE OF ERECTILE DYSFUNCTION SYMPTOMS WO 23.06.2016
A61F 6/04
PCT/IL2015/051220 ONE WORLD CANNABIS LTD SINAI, Alon
6. WO/2016/092539 USE OF CANNABIS TO TREAT MIGRAINE WO 16.06.2016
A61K 31/352
PCT/IL2015/051184 ONE WORLD CANNABIS LTD TURNER, Ziv
7. WO/2016/084075 SYNERGISTIC USE OF CANNABIS FOR TREATING MULTIPLE MYELOMA WO 02.06.2016
A61K 31/05
PCT/IL2015/051138 ONE WORLD CANNABIS LTD SINAI, Alon
Strategic manufacturing, distribution & marketing Alliances:
Medmar – Based in Maryland, certain rights to manufacture, produce, publicize, promote and market OWCP’s licensed products in the United States.
Michepro – A European distribution company which signed a Joint Venture agreement, 75% (OWCP) 25% (MICHEPRO Ltd), to set up a European entity to promote, manufacture and sell OWCP products in that region.
Team & Facility:
OWCP is led by a team of experienced professionals, having substantial experience in areas of medical cannabis, clinical research, healthcare management, international business and financial markets. This knowledge, alongside their commercial experience, is likely to help
Dr. Yehuda Baruch, who is leading OWCP’s overall operations as “chief scientist officer” and regulatory affairs, is a world renowned Psychiatrist, who founded, implemented and Headed the Israeli Medical Cannabis Unit under the Minister of Health for over 10 years.
Recent operational break-through:
It recently announced that it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical cream compound for the treatment of psoriasis and related skin conditions.
OWCP continues to make significant progress in R&D of cannabis-centric medical treatments, specifically with psoriasis cream, which is being readied for the U.S. and European markets. The company is focused on having products on the shelves in the MMJ states this year.
Lot to read, hope all found some nuggets in there.
First, Full proof of OWC being 100% Legit with fully filed and active clinical trials.
- updated filing of OWC Clinical Trials of .OWC MGC cream
https://clinicaltrials.gov/ct2/show/NCT029767...amp;rank=1
Responsible Party: One World Cannabis Ltd.
ClinicalTrials.gov Identifier: NCT02976779 History of Changes
Other Study ID Numbers: OWC-PSO-01
Who is this ClinicalTrials.GOV site?
ClinicalTrials.gov is a registry of clinical trials. It is run by the United States National Library of Medicine (NLM) at the National Institutes of Health, and is the largest clinical trials database, currently holding registrations from over 230,000 trials from 195 countries in the world.
OWC Pharmaceutical Research Analysis;
OWC Pharmaceutical Research Corp (OTCMKTS: OWCP), through its wholly owned Israeli subsidiary, One Word Cannabis Ltd., conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. OWCP is also developing unique delivery systems for the effective delivery and dosage of medical cannabis. All research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
In fact, the Israeli government is one of the few countries worldwide to approve clinical studies with cannabis.
The company recently announced that it received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical cream compound for treatment of psoriasis and related skin conditions.
Psoriasis cream is one of the major/critical business drivers for the company. It is in final round of efficacy testing before it hits shelves. Management confirmed that this approval is a significant milestone for the company & immediately after approval of psoriasis treatment formulation; OWCP began receiving requests for its topical psoriasis cream product from patients suffering from the condition.
OWCP further added, that after several years of extensive research, they now expect to launch psoriasis cream to the market during second quarter of 2017 or soon thereafter. Beyond psoriasis, it is also pushing multiple myeloma candidates through early stage trials, with the goal of getting the assets into clinical studies before the end of 2017.
OWCP operates in Marijuana industry that has rapidly & recently turned into a multi-billion dollar massive growth market across US and Canada with many new states legalizing it. According to a recent estimates, cannabis market crossed $6.7 billion from the U.S. alone in 2016, and that sale of cannabis are set to rise to $22.8 billion in the U.S. by 2020.
There are only a handful of publicly traded companies focused on meaningful, advanced stage cannabinoid-based, pharmaceutical development.
The growing popularity of this industry is seen as major inflection point for current licensed producers & researchers. In particular, existing cannabis players with sizable market cap & advanced stage product pipeline are expected to grow their (OWC) business with relatively lesser competitive threats.
OWCP is one of the promising entities for cannabis investors. The company has its own IP’s, which commands significant value.
Furthermore, as it move towards approval and commercialization process, the intrinsic value of the company is expected to increase significantly. With a seasoned management team, OWCP is at a critical inflection point.
Description & manufacturing set-up:
OWC Pharmaceutical, through its wholly owned subsidiary, One world Cannabis Ltd, conducts medical research and clinical trials to develop cannabis-based pharmaceuticals and treatments for conditions including multiple myeloma, psoriasis, fibromyalgia, PTSD, and migraines. It is also developing unique delivery systems for effective delivery and dosage of medical cannabis. All its research is conducted at leading Israeli hospitals and scientific institutions, and led by internationally renowned investigators.
One world Cannabis Ltd was set up in 2014 in Israel as a Wholly owned subsidiary of OWC Pharmaceutical Research Corp. (OTCQB:OWCP). One World offers OWCP with international access to the best research facilities and researchers in medicinal cannabis.
The state of Israel has been supportive of cannabis study and scientific research since 1960s’ in renown academic and research hospitals. The Medical Cannabis Unit under the Health Minister Office is operating in Israel since 2003.
Major Divisions of the Company:
R&D Division: All OWCP studies are following approved clinical procedures by IRB protocols conducted in Israeli hospitals facilities. Each new product targets a specific disease or medical conditions, with a particular emphasis on identifying unique formulation and efficient delivery systems to optimize the bioavailability of dosage.
Key Cannabis Based Products (IP owned by OWCP) – Likely to be commercialized:
Topical cream: Treatment for different skin diseases starting with tested psoriasis. Estimated market size ~8 Million Psoriasis patients US & Canada (2.5% of population).
Sublingual Soluble tablet: For conditions like, replacement of smoking & pain treatment. Estimated market size – more than 10 million potential patients in the approved MMJ states.
All OWCP Patents,
1. WO/2016/199148 NOVEL CANNABINOID COMBINATION THERAPIES FOR MULTIPLE MYELOMA (MM) WO 15.12.2016
A61K 31/352
PCT/IL2016/050608 ONE WORLD CANNABIS LTD SINAI, Alon
2. WO/2016/181394 USE OF CANNABIS TO TREAT FIBROMYALGIA, METHODS AND COMPOSITIONS THEREOF WO 17.11.2016
A61K 31/352
PCT/IL2016/050498 ONE WORLD CANNABIS LTD SINAI, Alon
3. WO/2016/147186 PREPARATIONS OF CANNABIS EMULSIONS AND METHODS THEREOF WO 22.09.2016
A61K 9/107
PCT/IL2016/050289 ONE WORLD CANNABIS LTD SINAI, Alon
4. WO/2016/103254 USE OF CANNABIS TO TREAT PSORIASIS WO 30.06.2016
A61K 31/352
PCT/IL2015/051234 ONE WORLD CANNABIS LTD SINAI, Alon
5. WO/2016/098112 NOVEL CONDOM COMPRISING CANNABIS DERIVED COMPOSITIONS FOR ENHANCEMENT OF SEXUAL PLEASURE AND DECREASE OF ERECTILE DYSFUNCTION SYMPTOMS WO 23.06.2016
A61F 6/04
PCT/IL2015/051220 ONE WORLD CANNABIS LTD SINAI, Alon
6. WO/2016/092539 USE OF CANNABIS TO TREAT MIGRAINE WO 16.06.2016
A61K 31/352
PCT/IL2015/051184 ONE WORLD CANNABIS LTD TURNER, Ziv
7. WO/2016/084075 SYNERGISTIC USE OF CANNABIS FOR TREATING MULTIPLE MYELOMA WO 02.06.2016
A61K 31/05
PCT/IL2015/051138 ONE WORLD CANNABIS LTD SINAI, Alon
Strategic manufacturing, distribution & marketing Alliances:
Medmar – Based in Maryland, certain rights to manufacture, produce, publicize, promote and market OWCP’s licensed products in the United States.
Michepro – A European distribution company which signed a Joint Venture agreement, 75% (OWCP) 25% (MICHEPRO Ltd), to set up a European entity to promote, manufacture and sell OWCP products in that region.
Team & Facility:
OWCP is led by a team of experienced professionals, having substantial experience in areas of medical cannabis, clinical research, healthcare management, international business and financial markets. This knowledge, alongside their commercial experience, is likely to help
Dr. Yehuda Baruch, who is leading OWCP’s overall operations as “chief scientist officer” and regulatory affairs, is a world renowned Psychiatrist, who founded, implemented and Headed the Israeli Medical Cannabis Unit under the Minister of Health for over 10 years.
Recent operational break-through:
It recently announced that it has received Institutional Review Board (IRB) approval to conduct safety testing on its proprietary topical cream compound for the treatment of psoriasis and related skin conditions.
OWCP continues to make significant progress in R&D of cannabis-centric medical treatments, specifically with psoriasis cream, which is being readied for the U.S. and European markets. The company is focused on having products on the shelves in the MMJ states this year.
Lot to read, hope all found some nuggets in there.
4
